Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

Cancer research - 1 Nov 2013

Zhou Bingsen, Su Leila, Hu Shuya, Hu Weidong, Yip M L Richard, Wu Jun, Gaur Shikha, Smith D Lynne, Yuan Yate-Ching, Synold Timothy W, Horne David, Yen Yun

Abstract excerpt

Ribonucleotide reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synthesis, growth, metastasis, and drug resistance of cancer cells. The current clinically established RNR inhibitors have the shortcomings of short half-life, drug resistance, and iron chelation. Here, we report the development of a novel class of effective RNR inhibitors addressing these issues. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine
Share to Gemcitabine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Half-Life

Share to Hydroxyurea

Share to Interleukin-2 Receptor alpha Subunit

Share to Ribonucleotide Reductases

Share to Small Molecule Libraries

Share to Surface Plasmon Resonance

Source

Open in PubMed Open full text

Identifiers

PMID: 24072748
DOI: 10.1158/0008-5472.CAN-13-1094
PMCID: PMC3823501

Genes

RRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.PMID 24072748Read ↗

Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and PresentSemantic proximity Read ↗

Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancerSemantic proximity Read ↗

Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral AgentsSemantic proximity Read ↗

TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stressSemantic proximity Read ↗

Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein.Semantic proximity Read ↗

Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Impact of N221S missense mutation in human ribonucleotide reductase small subunit b on mitochondrial DNA depletion syndrome.Semantic proximity Read ↗

Mutations in the R2 subunit of ribonucleotide reductase that confer resistance to hydroxyurea.Semantic proximity Read ↗

Inhibiting RRM2 to enhance the anticancer activity of chemotherapySemantic proximity Read ↗

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.Semantic proximity Read ↗

Ribonucleotide reductases: amazing and confusing.Semantic proximity Read ↗

Starting a new chapter on class Ia ribonucleotide reductasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.